Efficacy and Safety Evaluation in Recurrent Wheezing Attacks

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

February 28, 2017

Conditions
Bronchospasm; BronchiolitisBronchospasm; Bronchitis
Interventions
BIOLOGICAL

Biological vaccine

daily spray (2 puff of 100 µL) for six months

Trial Locations (2)

46026

Hospital Universitario y Politécnico La Fe, Valencia

46940

Hospital de Manises, Manises

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Unidad de Investigacion Medica en Epidemiologia Clinica

OTHER

lead

Inmunotek S.L.

INDUSTRY

NCT01734811 - Efficacy and Safety Evaluation in Recurrent Wheezing Attacks | Biotech Hunter | Biotech Hunter